Imbria Pharmaceuticals Is A Clinical Stage Biotechnology Company Based In Bostonmassachusettsfounded In 2018The Company Focuses On Developing Innovative Therapies For Cardiometabolic Disordersparticularly Cardiovascular Diseasesimbria Aims To Enhance Cellular Energy Production To Improve Patient Outcomesaddressing Significant Unmet Needs In Healthcare The Company S Main Product In Development Is Ninerafaxstatwhich Targets Non Obstructive Hypertrophic Cardiomyopathynhcmand Aims To Improve Cardiac Energetics And Patient Symptoms In Heart Failure With Preserved Ejection Fractionhfpef Imbria Has Secured Substantial Fundingincluding A Recent $57 5 Million Series B Financing Roundto Advance Ninerafaxstat Into A Phase 2B Clinical Trialthe Company Is Also Actively Engaged In Research And Developmentholding 31 Patents Related To Metabolism And Cardiac Health
